Three-dimensional quantitative structure-activity relationships of steroid aromatase inhibitors

SummaryInhibition of aromatase, a cytochrome P450 that converts androgens to estrogens, is relevant in the therapeutic control of breast cancer. We investigate this inhibition using a three-dimensional quantitative structure-activity relationship (3D QSAR) method known as Comparative Molecular Field Analysis, CoMFA [Cramer III, R.D. et al., J. Am. Chem. Soc., 110 (1988) 5959]. We analyzed the data for 50 steroid inhibitors [Numazawa, M. et al., J. Med. Chem., 37 (1994) 2198, and references cited therein] assayed against androstenedione on human placental microsomes. An initial CoMFA resulted in a three-component model for log(1/Ki), with an explained variance r2 of 0.885, and a cross-validated q2 of 0.673. Chemometric studies were performed using GOLPE [Baroni, M. et al., Quant. Struct.-Act. Relatsh., 12 (1993) 9]. The CoMFA/GOLPE model is discussed in terms of robustness, predictivity, explanatory power and simplicity. After randomized exclusion of 25 or 10 compounds (repeated 25 times), the q2 for one component was 0.62 and 0.61, respectively, while r2 was 0.674. We demonstrate that the predictive r2 based on the mean activity (Ym) of the training set is misleading, while the test set Ym-based predictive r2 index gives a more accurate estimate of external predictivity. Using CoMFA, the observed differences in aromatase inhibition among C6-substituted steroids are rationalized at the atomic level. The CoMFA fields are consistent with known, potent inhibitors of aromatase, not included in the model. When positioned in the same alignment, these compounds have distinct features that overlap with the steric and electrostatic fields obtained in the CoMFA model. The presence of two hydrophobic binding pockets near the aromatase active site is discussed: a steric bulk tolerant one, common for C4, C6-alpha and C7-alpha substitutents, and a smaller one at the C6-beta region.

[1]  Jeremy G. Vinter,et al.  Extended electron distributions applied to the molecular mechanics of some intermolecular interactions , 1994, J. Comput. Aided Mol. Des..

[2]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[3]  A. N. Jain,et al.  Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark. , 1994, Journal of medicinal chemistry.

[4]  A. Brodie,et al.  Aromatase inhibitors in the treatment of breast cancer , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[5]  Pui-Kai Li,et al.  Biochemical and pharmacological development of steroidal inhibitors of aromatase , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[6]  Ian A. Wilson,et al.  Molecular basis of crossreactivity and the limits of antibody–antigen complementarity , 1993, Nature.

[7]  Yvonne C. Martin,et al.  New strategies that improve the efficiency of the 3D design of bioactive molecules , 1993 .

[8]  Mitsuteru Numazawa,et al.  Synthesis of Androst‐5‐en‐7‐ones and Androsta‐3,5‐dien‐7‐ones and Their Related 7‐Deoxy Analogues as Conformational and Catalytic Probes for the Active Site of Aromatase. , 1994 .

[9]  Mitsuteru Numazawa,et al.  6α,7 ga-Cyclopropane derivatives of androst-4-ene: A novel class of competitive aromatase inhibitors , 1991 .

[10]  James J. P. Stewart,et al.  MOPAC: A semiempirical molecular orbital program , 1990, J. Comput. Aided Mol. Des..

[11]  M Numazawa,et al.  Synthesis of androst-5-en-7-ones and androsta-3,5-dien-7-ones and their related 7-deoxy analogs as conformational and catalytic probes for the active site of aromatase. , 1994, Journal of medicinal chemistry.

[12]  Thompson Ea,et al.  The Involvement of Human Placental Microsomal Cytochrome P-450 in Aromatization , 1974 .

[13]  S. Neidle,et al.  A detailed molecular model for human aromatase , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[14]  R. Hartmann,et al.  Aromatase inhibitors. Syntheses and structure-activity studies of novel pyridyl-substituted indanones, indans, and tetralins. , 1994, Journal of medicinal chemistry.

[15]  Y J Abul-Hajj,et al.  Aromatase inhibition by 4-thiosubstituted-4-androstene-3,17-dione derivatives. , 1990, Journal of steroid biochemistry.

[16]  P K Li,et al.  Synthesis and biochemical studies of 7-substituted 4,6-androstadiene-3,17-diones as aromatase inhibitors. , 1990, Journal of medicinal chemistry.

[17]  R. Brueggemeier,et al.  Steroidal inhibitors as chemical probes of the active site of aromatase , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[18]  Opera Ti,et al.  3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results. , 1994 .

[19]  D. Zhou,et al.  Functional domains of aromatase cytochrome P450 inferred from comparative analyses of amino acid sequences and substantiated by site-directed mutagenesis experiments. , 1992, The Journal of biological chemistry.

[20]  J. Topliss,et al.  Chance correlations in structure-activity studies using multiple regression analysis , 1972 .

[21]  D. E. Patterson,et al.  Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies , 1988 .

[22]  E. Simpson,et al.  Functional domains of human aromatase cytochrome P450 characterized by linear alignment and site-directed mutagenesis. , 1993, Molecular endocrinology.

[23]  K. Korzekwa,et al.  Mutagenesis study at a postulated hydrophobic region near the active site of aromatase cytochrome P450. , 1994, The Journal of biological chemistry.

[24]  J. Kellis,et al.  Purification and characterization of human placental aromatase cytochrome P-450. , 1987, The Journal of biological chemistry.

[25]  G. Cruciani,et al.  Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems , 1993 .

[26]  M Numazawa,et al.  19-Hydroxy-4-androsten-17-one: potential competitive inhibitor of estrogen biosynthesis. , 1989, Biochemical and biophysical research communications.

[27]  N. Peet,et al.  A-ring bridged steroids as potent inhibitors of aromatase , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[28]  T. Poulos,et al.  High-resolution crystal structure of cytochrome P450cam. , 1987, Journal of molecular biology.

[29]  B. Skagerberg,et al.  Predictive ability of regression models. Part I: Standard deviation of prediction errors (SDEP) , 1992 .

[30]  G R Marshall,et al.  3D-QSAR: a current perspective. , 1995, Trends in pharmacological sciences.

[31]  Chris M. W. Ho,et al.  De Novo Design: Ligand Construction and Prediction of Affinity , 1995 .

[32]  William Francis Ganong,et al.  Review of Medical Physiology , 1969 .

[33]  R. D'Alessio,et al.  4-aminoandrostenedione derivatives: A novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[34]  Shiuan Chen,et al.  Kinetic properties of aromatase mutants Pro308Phe, Asp309Asn, and Asp309Ala and their interactions with aromatase inhibitors , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[35]  Paul Geladi,et al.  Principal Component Analysis , 1987, Comprehensive Chemometrics.

[36]  T. Poulos,et al.  A site-directed mutagenesis study of human placental aromatase. , 1992, The Journal of biological chemistry.

[37]  J P Burkhart,et al.  Novel time-dependent inhibitors of human placental aromatase. , 1991, Journal of medicinal chemistry.

[38]  Shiuan Chen,et al.  Structure-function studies of human aromatase , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[39]  Tudor I. Oprea,et al.  Three-dimensional quantitative structure-activity relationship of human immunodeficiency virus (I) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes. , 1994, Journal of medicinal chemistry.

[40]  N. Peet,et al.  Biological characterization of A-ring steroids , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[41]  M Numazawa,et al.  Synthesis and biochemical studies of 16- or 19-substituted androst-4-enes as aromatase inhibitors. , 1991, Journal of medicinal chemistry.

[42]  Tudor I. Oprea,et al.  Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules. , 1993, Journal of medicinal chemistry.

[43]  M Numazawa,et al.  6-Alkyl- and 6-arylandrost-4-ene-3,17-diones as aromatase inhibitors. Synthesis and structure-activity relationships. , 1994, Journal of medicinal chemistry.

[44]  A. Panzeri,et al.  Novel aromatase and 5α-reductase inhibitors , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[45]  T. Hassard,et al.  Applied Linear Regression , 2005 .

[46]  D. Pompon,et al.  Structure-function studies of human aromatase by site-directed mutagenesis: kinetic properties of mutants Pro-308----Phe, Tyr-361----Phe, Tyr-361----Leu, and Phe-406----Arg. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[47]  K. Appelt,et al.  Crystal structures of HIV-1 protease-inhibitor complexes , 1993 .

[48]  Evan R. Simpson,et al.  Tissue-specific promoters regulate aromatase cytochrome P450 expression , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[49]  P. Li,et al.  7-substituted 1,4,6-androstatriene-3,17-diones as enzyme-activated irreversible inhibitors of aromatase. , 1990, Journal of steroid biochemistry.

[50]  G. Cruciani,et al.  Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b. , 1994, Journal of medicinal chemistry.

[51]  C. Wermuth,et al.  Trends in QSAR and Molecular Modelling 92 , 1993 .